Ozamore Cream contains Ozenoxacin 1% w/w, a non-fluorinated topical quinolone antibiotic indicated for the treatment of superficial bacterial skin infections such as impetigo. Ozenoxacin exhibits potent bactericidal activity against a broad spectrum of gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus pyogenes, by inhibiting bacterial DNA gyrase and topoisomerase IV enzymes, thereby preventing bacterial DNA replication and transcription. The cream formulation facilitates targeted delivery to the affected skin area, minimizing systemic absorption and reducing the risk of systemic side effects. Ozamore Cream is applied topically twice daily to the affected area for a duration typically ranging from 5 to 7 days, depending on clinical response. It is generally well tolerated, with adverse effects limited primarily to mild local reactions such as erythema, pruritus, or burning sensation at the application site. Ozamore Cream should be used with caution in patients with known hypersensitivity to quinolones or any cream excipients. It is contraindicated for use on mucous membranes or in extensive skin infections requiring systemic therapy. Proper hygiene and adherence to prescribed treatment duration are essential to prevent bacterial resistance and ensure optimal therapeutic outcomes.